



**EoI No. ICMR/EoI/PM/16/ Ulcerative Colitis/2026
Dated 14/05/2026**

Invitation for Expression of Interest (EoI)

For

Transfer of Technology

Of

**Development of an encapsulated cocktail of gut-microbiota-derived metabolites as a potential therapeutic modality for Ulcerative Colitis
(Therapeutics)**

By ICMR-Hqrs

Indian Council of Medical Research
(Department of Health Research, GoI)
V. Ramalingaswami Bhawan,
P.O. Box No. 4911, Ansari Nagar,
New Delhi - 110029, India

CONTENTS

Sl. No	Section	Page No.
1	Letter of Invitation	3
2	Background	4
3	Objective	4
4	Broad Scope of Work	4
5	Intellectual Property Rights	6
6	Process involved in Partnership/Collaboration/Technology Transfer	6
7	Publication	6
8	Data Rights	7
9	Details of documents to be furnished	7
10	Rejection Criteria	7
11	Evaluation Methodology	8
12	Pre-Qualification Criteria (PQC)	8-9
13	Disclaimer	9
14	Arbitration	9
15	Contacts for enquiry	10
16	Expression of Interest (Format – 1)	11-12
17	Authorization Letter (Format – 2)	13
18	Undertaking with regard to Blacklisting (Format-3)	14
19	Undertaking with regard to Non-Conviction (Format – 4)	15
20	Undertaking with regard to laboratory facility (Format – 5)	16
21	Production Capacity Undertaking (Format-6)	17
22	Schedule A - Technology Details	18

Letter of Invitation

1. Invitation for Expression of Interest

Indian Council of Medical Research (ICMR), New Delhi invites Expression of Interest (EoI) from the eligible organizations, companies, manufacturers for undertaking ‘**Transfer of Technology**’ for commercialization of “Development of an encapsulated cocktail of gut-microbiota-derived metabolites as a potential therapeutic modality for Ulcerative Colitis” useful in Therapeutic modality for Ulcerative Colitis.

The EoI document containing the details of qualification criteria, submission details, brief objective & scope of work and evaluation criteria etc. can be downloaded from the ICMR website (<https://www.icmr.gov.in>).

Schedule for the Proponents is as under:

EoI Document Number	ICMR/EoI/PM/16/ Ulcerative Colitis/2026
Date of Publication	Date: 14/05/2026
Last date of submission	Date: 20/05/2026

Note:

Interested applicants are invited to submit their Expression of Interest (EoI) through the Medical Innovation Patent Mitra portal (<https://patentmitra.icmr.org.in/companyeoirregistration/>). Applicants must first register by providing requisite company information, including details of the authorized representative. Upon successful registration, applicants are required to complete and submit the e-EoI form available on the portal.

ICMR reserves the right to cancel this EoI and/ or invite afresh with or without amendments, without liability or any obligation for such EoI and without assigning any reason. Information provided at this stage is indicative and ICMR reserves the right to amend/add any further details in the EoI, as may be desired by the Competent Authority ICMR and duly notified on its website.

2. Background

The Indian Council of Medical Research (ICMR), New Delhi, the apex body in India for the formulation, coordination and promotion of biomedical research, is one of the oldest medical research bodies in the world. The ICMR has always attempted to address the growing demands of scientific advances in biomedical research on the one hand and the need of finding practical solutions to the health problems of the country, on the other.

Dr. Vineet Ahuja from AIIMS, New Delhi has developed a technology entitled “Development of an encapsulated cocktail of gut-microbiota-derived metabolites as a potential therapeutic modality for Ulcerative Colitis” (hereinafter) referred to as **“Technology”** and has applied for technology transfer support under **ICMR Medical Innovations Patent Mitra initiative**.

ICMR under its “Medical innovations Patent Mitra” initiative is taking the initiative to enter into any form of **Non-exclusive agreements** with eligible manufacturing companies hereinafter referred to as the **“Company”** through a defined agreement for Licensing/Commercialization of “Development of an encapsulated cocktail of gut-microbiota-derived metabolites as a potential therapeutic modality for Ulcerative Colitis”, hereinafter referred to as the **‘Product’**, which shall be governed by Policy applicable to the Institute.

3. Objective

To license the ‘Technology’ for “Development of an encapsulated cocktail of gut-microbiota-derived metabolites as a potential therapeutic modality for Ulcerative Colitis”, useful in “Therapeutic modality for Ulcerative Colitis”, for commercialization and marketing activities.

4. Scope of Work

- i. ICMR under its “Medical Innovations Patent Mitra” initiative is willing to collaborate with eligible organizations, companies, and manufacturers for undertaking Transfer of technology and commercialization of the Technology/product entitled “Development of an encapsulated cocktail of gut-microbiota-derived metabolites as a potential therapeutic modality for Ulcerative Colitis”.
- ii. The Company would be granted rights to undertake further development, manufacture, sell, and commercialize the Technology/Product “Development of an encapsulated cocktail of gut-microbiota-derived metabolites as a potential therapeutic modality for Ulcerative Colitis”.
- iii. An Agreement (in case of joint development or licensing) following EoI is proposed to be executed on a “Non-Exclusive” basis with single/multiple companies to enable wider outreach of the Technology/product entitled “Development of an encapsulated cocktail of gut-microbiota-derived metabolites as a potential therapeutic modality for Ulcerative Colitis” for societal benefit and public health use. All the related issues shall be governed by IP Policy applicable to AIIMS, New Delhi.
- iv. Dr. Vineet Ahuja, from AIIMS, New Delhi has expertise in various techniques, methods and information relating to aforesaid technology which could be used for the production of

the Technology/product entitled “Development of an encapsulated cocktail of gut-microbiota-derived metabolites as a potential therapeutic modality for Ulcerative Colitis”.

Role of Institute

- i. **Dr. Vineet Ahuja from AIIMS, New Delhi** will provide expert guidance & technical support for the production of the Technology/product entitled “Development of an encapsulated cocktail of gut-microbiota-derived metabolites as a potential therapeutic modality for Ulcerative Colitis”, in all phases. Such technical oversight by **Dr. Vineet Ahuja from AIIMS, New Delhi** would accelerate the development of the Product and its commercialization.
- ii. ICMR & AIIMS, New Delhi shall have no financial implication unless otherwise specified.

Role of AIIMS, New Delhi

- i. The Company shall have valid provisions to provide all necessary infrastructure/ material/ manpower required for product development/ validation/ scale-up either directly or otherwise.
- ii. The Company shall be responsible for obtaining all the regulatory approvals required for commercialization or starting from R&D for product development to its commercialization.

5. Intellectual Property Rights

It is submitted that in case of transfer of Technology, Dr. Vineet Ahuja from AIIMS, New Delhi is the sole owner of the said Technology, including any underlying Intellectual Property(ies) and commercialization rights.

Intellectual Property (IP) shall mean patents, rights to inventions, copyright and related rights, moral rights, rights in designs, rights in trademarks, rights to preserve the confidentiality of information (including know-how and trade secrets) and any other intellectual property rights, in each case whether registered or unregistered and including all applications (or rights to apply for and be granted), divisional, continuations, continuations-in-part, reissues, renewals or extensions of, and rights to claim priority from, such rights and all similar or equivalent rights or forms of protection which subsist or will subsist now or in the future in any part of the world regarding subject matter disclosed in Licensed patents.

Dr. Vineet Ahuja from AIIMS, New Delhi legally possess the rights and authority to retain full or part of the ‘Technology’ by itself or to assign at its discretion full or part of the Technology including any patent(s) or intellectual property rights(s) or the invention(s), and can enter into any form of non-exclusive License Agreements with selected companies including transfer of the Technology through suitable Agreement(s).

In case of collaboration between Institute and the Company for the Joint development of the

Technology/ Product, Background Intellectual Property (“BGIP”) shall always remain the sole and exclusive property of the Party generating the BGIP. Any IP, if generated during the course of collaboration, including any improvement thereof, shall be jointly owned by the parties. All such provisions related to intellectual property rights shall be governed IP Policy of AIIMS, New Delhi.

6. Process involved in Partnership/Collaboration/Technology Transfer

Interested companies/manufacturers are invited to join hands with Innovator for co-development/ further development & commercialization of the Technology/ Product(s). Under this EoI, the manufacturers/companies who are responsive and fulfilling all the technical need will be shortlisted based on their R&D plan, facilities and capabilities. Qualified companies/manufacturers will only be contacted for execution of MoA/MoU/Agreement for partnership/collaboration/technology transfer, etc. Subsequent to the execution of the Agreement such companies/manufacturers shall be responsible to pay the Royalty, as applicable, according to the IP Policy of AIIMS, New Delhi.

7. Publication

- i. In case of Co-development, the Parties shall have equal rights on the manuscripts/scientific publications (joint publication/acknowledgment /other credits as applicable) and in accordance with guidelines of International Committee of Medical Journal Editors (ICMJE.org).
- ii. Support of ICMR must be duly acknowledged in all publications by the parties.

8. Data Rights

- i. Data Rights will be exclusively with ICMR, if ICMR provide 100% funding.
- ii. Data rights shall be jointly owned by Institute/Organization/University and Licensee/Co-developer, in case of joint funding.
- iii. Data rights in cases where Artificial Intelligence is involved shall be dealt separately.
- iv. Licensee/ Company to ensure that data is anonymized, kept confidential and strictly abide by the provisions of Information Technology Act, 2000 while dealing with such data

9. Details of documents to be furnished

Proponents are requested to go through all pre-qualification requirements, scope of work for execution & requirements with respect to technical capabilities for submission of interest, subject for verification by ICMR.

Documents to be furnished are as follows:

- i. Declaration - Expression of Interest (Format – 1)
- ii. Authorization Letter (Format – 2)
- iii. Undertaking with regard to Blacklisting (Format-3)
- iv. Undertaking with regard to Non-Conviction (Format – 4)

- v. EoI document with each page duly stamped and signed by the Authorized signatory.
- vi. Undertaking with regard to laboratory facility (Format – 5)
- vii. Production Capacity Undertaking (Format-6)
- viii. Supporting documents, as mentioned in Format-1
- ix. MSME Certificate (if applicable)
- x. Concept note on business plan- A brief concept note on R&D, clinical studies, planning & execution, production, marketing etc. with timeline (not more than 5 pages)
- xi. Any other information which proponent may wish to provide to support the EoI.

ICMR reserves the right to call for any clarifications confined in the broad scope, wherever such a clarification become necessary for proper judgement in evaluation.

10. Rejection Criteria

The application is liable to be rejected if:

- i. The proposal is not submitted as per the requirements indicated in the EoI.
- ii. Not in the prescribed format.
- iii. Not properly stamped and signed.
- iv. Received after the expiry of due date and time.
- v. All relevant supporting documents are not furnished with the Pre-Qualification Criteria (PQC).
- vi. The proposal shall be substantially responsive without any material deviation, failing which the proposal shall be summarily rejected.
- vii. Applications not fulfilling the terms of the document will be summarily rejected.
- viii. Any other non-compliance.

11. Evaluation Methodology

Screening of EoIs shall be carried out as per Pre-Qualification criteria mentioned in the EoI document and based on verification of documents submitted.

12. Pre-Qualification Criteria (PQC)

The following will be the minimum Pre-Qualification Criteria (PQC). Responses not meeting the minimum PQC will be summarily rejected and will not be evaluated further:

Sl. No.	Pre-Qualification Criteria (General)	Supporting copy of documents required (All documents must be self-attested by the authorized person of the proponent)
General Criteria		

1	The proponent shall be a legal entity, registered as Institution/Company/ LLP/ Society/ partnership firm/ proprietorship firm under respective acts in India and shall have more than 51% of Company stakes by promoters from India.	Registration of firm/ organization/Company Incorporation Certificate from Registrar of Companies (ROC) /Partnership deed etc. whichever is applicable
2	The proponent must be registered in India with taxation and other administrative authorities.	GST Registration or GST exemption certificate/ PAN Card
3	The proponent should have proven prior experience of manufacturing and/or R&D with manufacturing during the last three years, either in-house or through agreed collaboration and must have marketed same/similar products in the past with a good track record.	Research paper/Pamphlet / brochure of the product/DCGI License for existing product. Supporting documents for collaboration, if any.
4	The proponent has to be profitable and should not have incurred overall loss in past three (3) years. (applicable on commercial firms/organizations only)	Certificate from the Chartered Accountant of the Organization/ Audited Balance sheets for last three financial years or Income Tax return.
5	The proponent should have good track record and currently not black-listed/ barred by any Central / State Government / Public Sector Undertaking, Govt. of India, (applicable on commercial firms/organizations only).	Undertaking on the Letter Head of the Proponent duly signed & Stamped by Authorized Signatory (As per format – 3).
6	The proponent should have a manufacturing unit in India.	Registration copies/ factory license/ DSIR certificate, if have any.
7	The proponent and its promoters should not have been convicted for any offence in India by any competent court or judicial body during the past 3 years.	Undertaking on Proponent's Letter Head, duly signed and stamped by the Authorized Signatory (As per format – 4)
8	GMP/ quality certification (ISO or approved Indian certification) of manufacturing facility and GLP/ necessary certifications for R & D	Copies of Certificates
Specific Criteria (Based on the nature of the Proposal)		
9.	The proponent should have functional laboratory to carryout R&D for the product development	Undertaking on Proponent's Letter Head, duly signed and stamped by the Authorized Signatory (As per format – 5)
10.	Capacity to produce at least.....(quantity) per week	Undertaking (As per format – 6)

NOTE- For MSMEs and Start-ups, Start-Up-India, Make-in-India and other relevant guidelines of Government of India shall be applicable

13. Disclaimer

- i. ICMR shall not be responsible for any late receipt of applications for any reasons whatsoever.
- ii. ICMR reserves the right to cancel the call for EoI without assigning any reasons thereof.
- iii. ICMR may relax or waive any of the conditions stipulated in this document as deemed necessary in the best interest of the ICMR without assigning any reasons thereof.
- iv. To include any other item in the Scope of work at any time after consultation with proponents or otherwise.
- v. For International Clients, please note that EoI and other necessary correspondences shall be submitted in English only.

14. Arbitration

That any dispute and/ or any part of the dispute which couldn't be resolved through mutual consultation, the same shall be referred to the sole arbitrator as per the Arbitration & Conciliation Act, 1996 and any amendment thereafter. The Venue and Seat of the arbitration proceedings shall be New Delhi and the courts at New Delhi will have exclusive jurisdiction.

15. Contacts

In case of any clarification required, please contact:

For scientific issues-

Dr. Vineet Ahuja

Email: vineet.aiims@gmail.com , Mobile No.: 9810707170

For EOI related Technical issues-

Medical Innovations Patent Mitra Team,

Email: patentmitra.hq@icmr.gov.in

Format-1

Expression of Interest

(To be submitted on Company's Letter Head)

To,

The Director General,
Indian Council of Medical Research,
Ansari Nagar, New Delhi.

Subject: Submission of Expression of Interest (EoI) for Transfer of Technology for the Technology entitled "Development of an encapsulated cocktail of gut-microbiota-derived metabolites as a potential therapeutic modality for Ulcerative Colitis" and manufacturing, commercialization of Diagnostic assay/ Kit useful in therapeutic modality for Ulcerative Colitis.

Ref: ICMR/EoI/PM/16/ Ulcerative Colitis/2026 dated 14/05/2026

Sir,

The undersigned having read and examined in detail all the EoI documents pertaining to your transfer of technology and do hereby express the interest to undertake the research & development/manufacture/ sale /commercialization of the product as mentioned in the EoI document. The details of the Company and contact person are given below:

Name of the Proponent	
Address	
Name, designation & address of the person (to whom all communications shall be made)	
Telephone No. (with STD code)	
Mobile No. of the contact person	
Email ID of the contact person	

The following documents are enclosed:

Sl. No.	Documents required	Type of document attached	Page No.
1	Company Incorporation Certificate from ROC/Partnership deed etc.		

2	GST Registration or GST exemption certificate/ PAN Card.		
3	DCGI/CDSCO license for the existing products available in the market		
4	Certificate from the Chartered Accountant of the Organization/ Audited Balance sheets for las three financial years, Income Tax return.		
5	Proof of a registered office and a manufacturing Unit in India. Including DSIR certificate		
6	GMP/ GLC and ISO Certification. Registration copies of both		
7	Authorization Letter	As per format – 2	
8	Undertaking on the Letter Head of the Proponent duly signed & Stamped by Authorized Signatory	As per format – 3	
9	Undertaking on Proponent's Letter Head, duly signed and stamped by the Authorized Signatory	As per format – 4	
10	MSME Certificate (if have any)		
11	Business Plan	A brief concept note on planning & execution, production, marketing etc. (not more than 5 pages)	

I/we hereby declare that my/our EoI is made in good faith and the information contained is true and correct to the best of my/our knowledge and belief.

Thanking you,

Yours faithfully,

(Signature of the Authorized signatory)

Name:

Designation:

Seal:

Place:

Format-2

Authorization Letter

(To be submitted on Company's Letter Head)

To,

The Director General,
Indian Council of Medical Research,
Ansari Nagar, New Delhi.

Subject: Letter for Authorized Signatory

Ref: ICMR/EoI/PM/16/Ulcerative Colitis/2026 dated 14/05/2026

Sir,

This has reference to your above-mentioned Expression of Interest (EoI) for Transfer of Technology entitled "Development of an encapsulated cocktail of gut-microbiota-derived metabolites as a potential therapeutic modality for Ulcerative Colitis" and manufacturing, commercialization of Diagnostic assay/ Kit useful in therapeutic modality for Ulcerative Colitis.

Mr./Ms./Mrs./Dr.....is hereby authorized to submit the EoI documents and participate in the processing on behalf of M/s..... (Company Name), who's signature is below.

(Specimen Signature of Representative)

Date:

Place:

Yours faithfully,

(Signature of the Authorized signatory)

Name:.....

Designation:.....

Seal:.....

Format-3

Undertaking with regard to blacklisting
(To be submitted on Company's Letter Head)

To,

The Director General,
Indian Council of Medical Research,
Ansari Nagar, New Delhi.

Subject: Undertaking regarding Blacklisting / Non-Debarment.

Ref: ICMR/EoI/PM/16/ Ulcerative Colitis/2026 dated 14/05/2026

Sir,

It is hereby confirmed and declared that M/s.....(Company Name) currently has not been blacklisted / debarred by any Government Department / Public Sector Undertaking / or any other company for which works/assignments/services have been executed / undertaken.

Yours faithfully,

(Signature of the Authorized signatory)

Name:

Designation:

Seal:

Place:

Format-4

Undertaking with regard to Non-Conviction

(To be submitted on Company's Letter Head)

To,

The Director General,
Indian Council of Medical Research,
Ansari Nagar, New Delhi.

Subject: Undertaking regarding Non-Conviction.

Ref: ICMR/EoI/PM/16/ Ulcerative Colitis/2026 dated 14/05/2026

Sir,

It is hereby confirmed and declared that M/s.....(Company Name) and owner of the firm / board of directors, have not been convicted for any offence in India by any competent court or judicial body during the past 3 years.

Yours faithfully,

(Signature of the Authorized signatory)

Name:

Designation:

Seal:

Place:

Format-5

Undertaking with regard to laboratory facility

(To be submitted on Company's Letter Head)

To,

The Director General,
Indian Council of Medical Research,
Ansari Nagar, New Delhi.

Subject: Undertaking regarding laboratory infrastructure.

Ref: ICMR/EoI/PM/16/ Ulcerative Colitis/2026 dated 14/05/2026

Sir,

It is hereby confirmed and declared that M/s..... (Company Name) do have

- i. Adequate laboratory infrastructure (equipped laboratory facility). Please tick BSL-2/BSL-3/ABSL-3/GMP/GLP/ Other* (if other please specify) and
- ii. Adequate no. of experienced staff/skilled manpower to undertake manufacture/ research/ commercialization of the Technology entitled "Development of an encapsulated cocktail of gut-microbiota-derived metabolites as a potential therapeutic modality for Ulcerative Colitis" and manufacturing, commercialization of Diagnostic assay/ Kit useful in therapeutic modality for Ulcerative Colitis.

Yours faithfully,

(Signature of the Authorized signatory)

Name:

Designation:

Seal:

Place:

Format-6

Undertaking with regard to production capacity

(To be submitted on Company's Letter Head)

To,

The Director General,
Indian Council of Medical Research,
Ansari Nagar, New Delhi.

Subject: Undertaking with regard to production capacity.

Ref: ICMR/EoI/PM/16/ Ulcerative Colitis/2026 dated 14/05/2026

Sir,

It is hereby confirmed and declared that M/s..... does have the capacity in all mean (including infrastructure, fund, material, staff etc.) for manufacturing of (Name of Technology/ Product), minimum.....(mention the quantity per week/per month).

Yours faithfully,

(Signature of the Authorized signatory)

Name:

Designation:

Seal:

Place:

SCHEDULE-A
TECHNOLOGY DETAILS

PM Ref. ID: PM-TT-MC-2026-Apr-43

i. About the Technology/Product/Process:

Overview The innovation relates to the field of therapeutics, wherein a defined combination of gut microbiota-derived metabolite cocktails is used to recapitulate the anti-inflammatory effects of Faecal Microbiota Transplantation (FMT), while overcoming the risks and safety concerns associated with the transplantation of crude faecal material.

Technological aspects: The core functionality of this invention rests on the principle of multi-pathway microbiome modulation. Rather than targeting a single inflammatory mechanism, it combines multiple metabolites in a synergistic formulation designed to simultaneously intervene across several pathological axes of IBD.

Innovative Aspects: The principal innovation lies in its combination therapy design paradigm. IBD is a complex, chronic inflammatory condition arising from the interaction of immune, microbial, environmental, and genetic factors. Existing microbiome-based therapeutics, by targeting single pathways or employing single bacterial strains or metabolites, are inherently limited in their capacity to address this multifactorial pathology.

ii. Need and utility of the Technology from Public health perspective:

Epidemiological Context and Disease Burden Inflammatory Bowel Disease (IBD), encompassing Ulcerative Colitis (UC) and Crohn's Disease (CD), represents one of the most significant chronic gastrointestinal disorders globally. These conditions are characterised by persistent gut microbial dysbiosis, immune dysregulation, and progressive mucosal inflammation. As a result, they experience a deterioration in quality of life, a longer time to remission, and an elevated probability of relapse. India has witnessed a marked epidemiological transition over the last decade, emerging as the nation with the second-largest IBD-afflicted population in the world, with over 1.5 million patients currently diagnosed. India's unique ethnic genotype, dietary habits, and environmental conditions play significant roles in shaping the gut microbiome composition and, consequently, the nature and severity of the inflammatory response characteristic of UC. This growing disease burden imposes substantial clinical, social, and economic strain on the Indian healthcare system. Limitations of Current Therapeutic Approaches Conventional management of IBD relies primarily on immunosuppressive agents, corticosteroids, aminosalicylates, and biological therapies. While these approaches offer symptomatic relief, they are associated with significant limitations:

- They do not address the underlying gut microbial dysbiosis that drives and perpetuates IBD pathophysiology. Long-term immunosuppressive therapy carries risks of infection,

malignancy, and systemic adverse effects.

- A substantial proportion of patients exhibit primary non-response or develop secondary loss of response to biological agents. Fecal Microbiota Transplantation (FMT), though promising, is limited by donor variability, standardisation challenges, and regulatory hurdles. Societal Benefits This invention addresses a critical unmet medical need by offering a targeted, microbiome-modulating combination therapy that moves beyond symptomatic management to address the aetiological basis of IBD.

Economic Benefits: The global microbiome therapeutics market is currently valued at USD 0.66 billion and is projected to reach USD 3.17 billion by 2029, at a compound annual growth rate (CAGR) of 24.95%. The Indian microbiome therapeutics market, valued at USD 139.1 million, is expected to grow to USD 282 million by 2031 (CAGR: 6.9%). This invention is strategically positioned to contribute to and benefit from this expanding market. The economic benefits include: Reduction in long-term healthcare expenditure associated with chronic IBD management, hospitalization, and biological therapy costs. • Stimulation of investment and innovation within India's nascent but rapidly growing microbiome therapeutics ecosystem. Generation of licensing, technology transfer, and royalty revenues through B2B pharmaceutical partnerships.

- Potential for global export, particularly to Western markets where microbiome-based IBD therapeutics command significant commercial value.

iii. **Technology Readiness level (TRL): TRL-5**

iv. **Validation Status and outcome:**

We investigated the efficacy of metabolite cocktails using patient-derived intestinal organoids by assessing the viability, barrier integrity and inflammatory gene expression. Pre-clinical validation was subsequently conducted in a DSS-induced colitis model, in comparison with standard therapies, to determine therapeutic outcomes, including disease severity, histopathological damage, and modulation of intestinal inflammation.

v. **IP Filing Status/Publications**

IP Filing: Indian Patent Filed-IN202511124871

Date of Filing: 10/12/2025

Name of Inventor(s): Dr Vineet Ahuja, Dr. Saurabh Kedia, Radha Tiwari, Durga Devi Balakrishnan, Dr. Aditya Bajaj, Dr. Manasvini Markandey, Dr. Amit Awasthi, Dr.

Anurag Rathore, Dr. Rajdeep Dalal

Applicant: Dr. Vineet Ahuja

Publications: Nil
